137 related articles for article (PubMed ID: 17638860)
1. Development of vaccines for high-risk ductal carcinoma in situ of the breast.
Czerniecki BJ; Roses RE; Koski GK
Cancer Res; 2007 Jul; 67(14):6531-4. PubMed ID: 17638860
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
Czerniecki BJ; Koski GK; Koldovsky U; Xu S; Cohen PA; Mick R; Nisenbaum H; Pasha T; Xu M; Fox KR; Weinstein S; Orel SG; Vonderheide R; Coukos G; DeMichele A; Araujo L; Spitz FR; Rosen M; Levine BL; June C; Zhang PJ
Cancer Res; 2007 Feb; 67(4):1842-52. PubMed ID: 17293384
[TBL] [Abstract][Full Text] [Related]
3. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal alterations associated with the transition from in situ to invasive breast cancer.
Ellsworth RE; Vertrees A; Love B; Hooke JA; Ellsworth DL; Shriver CD
Ann Surg Oncol; 2008 Sep; 15(9):2519-25. PubMed ID: 18622645
[TBL] [Abstract][Full Text] [Related]
5. Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast.
Hanley K; Wang J; Bourne P; Yang Q; Gao AC; Lyman G; Tang P
Hum Pathol; 2008 Mar; 39(3):386-92. PubMed ID: 18187183
[TBL] [Abstract][Full Text] [Related]
6. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
7. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.
Sharma A; Koldovsky U; Xu S; Mick R; Roses R; Fitzpatrick E; Weinstein S; Nisenbaum H; Levine BL; Fox K; Zhang P; Koski G; Czerniecki BJ
Cancer; 2012 Sep; 118(17):4354-62. PubMed ID: 22252842
[TBL] [Abstract][Full Text] [Related]
8. The molecular journey from ductal carcinoma in situ to invasive breast cancer.
Wiechmann L; Kuerer HM
Cancer; 2008 May; 112(10):2130-42. PubMed ID: 18383519
[TBL] [Abstract][Full Text] [Related]
9. The dilemma of DCIS.
Morrow M; O'Sullivan MJ
Breast; 2007 Dec; 16 Suppl 2():S59-62. PubMed ID: 17714949
[TBL] [Abstract][Full Text] [Related]
10. The management of ductal carcinoma in situ: current controversies and future directions.
Masson S; Bahl A
Clin Oncol (R Coll Radiol); 2013 May; 25(5):275-82. PubMed ID: 23453783
[TBL] [Abstract][Full Text] [Related]
11. Biological variables and prognosis of DCIS.
van de Vijver MJ
Breast; 2005 Dec; 14(6):509-19. PubMed ID: 16246564
[TBL] [Abstract][Full Text] [Related]
12. Biology of ductal carcinoma in situ classification based on biologic potential.
Tsikitis VL; Chung MA
Am J Clin Oncol; 2006 Jun; 29(3):305-10. PubMed ID: 16755185
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast.
Meijnen P; Oldenburg HS; Peterse JL; Bartelink H; Rutgers EJ
Ann Surg Oncol; 2008 Jan; 15(1):235-43. PubMed ID: 17987342
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous mammary intraepithelial lesions in dogs--a model of breast cancer.
Antuofermo E; Miller MA; Pirino S; Xie J; Badve S; Mohammed SI
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2247-56. PubMed ID: 17982119
[TBL] [Abstract][Full Text] [Related]
16. Recent advances and current controversies in the management of DCIS of the breast.
Sakorafas GH; Farley DR; Peros G
Cancer Treat Rev; 2008 Oct; 34(6):483-97. PubMed ID: 18490111
[TBL] [Abstract][Full Text] [Related]
17. [The treatment of ductal carcinoma in situ (DCIS) of the breast].
Voogd AC; Ernst MF
Ned Tijdschr Geneeskd; 2004 Mar; 148(10):505-6; author reply 506. PubMed ID: 15042903
[No Abstract] [Full Text] [Related]
18. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
19. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS.
Fracol M; Xu S; Mick R; Fitzpatrick E; Nisenbaum H; Roses R; Fisher C; Tchou J; Fox K; Zhang P; Czerniecki BJ
Ann Surg Oncol; 2013 Oct; 20(10):3233-9. PubMed ID: 23851609
[TBL] [Abstract][Full Text] [Related]
20. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
